|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
1/24/2013 9:04:18 AM
DURHAM, N.C.--(BUSINESS WIRE)--New guidance from a British health agency released earlier this month supports the use of an ultrasound bone healing device that can be an alternative to surgery for thousands of patients with ‘problem’ fractures. The agency, the National Institute for Health and Clinical Excellence (NICE), provides evidence-based guidance about medicines, treatments, procedures and devices that represent the best quality care and which offer the best value for the money for England’s National Health Service (NHS), the world’s largest publicly funded health service. The guidance from NICE assessed both the clinical effects and the potential cost savings of the EXOGEN® Ultrasound Bone Healing System, which uses a unique ultrasound signal to stimulate broken bones to heal naturally, in comparison to surgical management. The product, manufactured by U.S.-based Bioventus LLC and distributed in the UK by Smith & Nephew, has been used worldwide since 1997 and is currently the market leader in the US for fracture stimulation.
|
|
|
|
|
|
|
|
|
|
|